J.H. Whitney sells 15 million Aveanna shares at $11.75, a week after the company raised guidance. Aveanna receives none of the money.

by Ellis Vance · August 21, 2026

Small-Cap Markets Correspondent, The SmallCap Signal

Aveanna Healthcare Holdings (Nasdaq: AVAH) said it has priced a secondary offering of 15,000,000 shares of common stock at $11.75 per share, and was explicit about who gets the proceeds. "The Company is not offering any shares of its common stock in the Offering and will not receive any of the proceeds from the sale of the shares offered by the Selling Stockholders," the release states.

The sellers, according to the company's announcements, are affiliates of J.H. Whitney Equity Partners VII, LLC together with certain current and former directors and officers of Aveanna. The J.H. Whitney affiliates have also granted the underwriter a 30-day option to buy up to 2,250,000 additional shares. RBC Capital Markets is acting as sole book-running manager. The offering is expected to settle on Aug. 24, subject to customary closing conditions.

Aveanna announced the launch of the offering on Thursday, Aug. 20, and priced it that same evening. The GlobeNewswire pricing release carries an "ATLANTA, Aug. 20, 2026" dateline; StockTitan timestamps the announcement at 8:16 p.m. ET on Aug. 20; and RTTNews reported the pricing in a story timed 9:51 p.m. ET that night. The GlobeNewswire web address for the release is dated Aug. 21 because 8:16 p.m. ET on Aug. 20 is 00:16 UTC on Aug. 21 — the wire's URL carries the UTC date, not the Eastern one. The pricing was a Thursday-night event.

The scale matters. Stockanalysis.com listed Aveanna with about 218.22 million shares outstanding and a market capitalization of roughly $2.83 billion. Fifteen million shares is therefore close to 6.9% of the share count, and 17.25 million shares — the deal plus the full option — would be about 7.9%. That is a large block to move through the market in a single night.

The pricing came at a discount. Aveanna closed Thursday at $12.97, a level reported both by stockanalysis.com and by RTTNews, which described it as a 1.44% decline on the day; $11.75 is 9.4% below that close, on our arithmetic from those two figures. RTTNews, writing at 9:51 p.m. ET Thursday, had the stock at $11.85 in after-hours trading, still above the offer price. It traded below the offer price the next morning: Benzinga's premarket roundup, published at 8:02 a.m. ET on Friday, Aug. 21, showed Aveanna at $11.65, down 10.2% against Thursday's close, and attributed the move to the secondary. Friday's regular session had not closed at the time of writing and no closing price for Aug. 21 was available.

What makes the timing conspicuous is that the sale lands seven days after Aveanna raised its full-year outlook. In results released Aug. 13, the company reported second-quarter revenue of $670.5 million, up 13.7% year over year, GAAP net income of $40.3 million against $27.0 million a year earlier, and adjusted EBITDA — a non-GAAP measure — of $95.4 million, up 8.0%.

All three segments grew. Private Duty Services revenue was $553.9 million, up 14.0%; Home Health & Hospice was $69.0 million, up 14.8%; and Medical Solutions was $47.5 million, up 9.4%. For the first six months, revenue reached $1,318.4 million, up 14.8%, with net income of $81.9 million versus $32.2 million.

Alongside those results Aveanna lifted its 2026 guidance to revenue of more than $2.68 billion, from a prior range of $2.63 billion to $2.65 billion, and adjusted EBITDA of more than $365 million, up from $338 million to $342 million. Chief financial officer Matt Buckhalter said in the release that the increased guidance "underscores the strength of our business model and the opportunities ahead as we continue to execute on our strategic initiatives."

The same release contains a less flattering line. Gross margin fell to 32.6% in the quarter from 35.8% a year earlier, and field contribution margin declined to 18.1% from 20.5%. Adjusted EBITDA grew 8.0% while revenue grew 13.7% — the gap between those two numbers is the margin compression in a single figure. Revenue is being added faster than profit.

Leverage is the other item on the page. Aveanna reported cash of $97.2 million and total debt of $1,483.4 million as of the quarter, with $225.5 million of undrawn revolver capacity. Measured against the floor of the company's own raised guidance — more than $365 million in adjusted EBITDA, a non-GAAP measure — gross debt is about 4.1 times that figure and net debt about 3.8 times, on our arithmetic from the disclosed numbers; if adjusted EBITDA lands above the floor, both multiples come down. First-half operating cash flow was $85.3 million and free cash flow $75.4 million.

Chief executive Jeff Shaner tied the quarter to the company's payor strategy, saying results "reinforce the strength of our operating model, the continued success of our Preferred Payor and Government Affairs strategies, and the dedication of our team to deliver exceptional care to patients and families." Aveanna's forward-looking statements flag risks tied to Medicare and Medicaid rate changes and to implementation of the One Big Beautiful Bill Act — reimbursement exposure that is structural for a business built on home nursing hours.

None of this is dilution in the technical sense: no new shares are being created and Aveanna's share count does not change. But the practical effect on the tape is similar, because the supply has to be absorbed by someone, and Thursday's close sat near the top of a 52-week range that stockanalysis.com showed as $5.93 to $13.40. A financial sponsor choosing to sell into that level, at a discount, is information — though it is information about the sponsor's own portfolio decisions as much as about Aveanna, and the releases do not disclose how much of its position J.H. Whitney retains after the offering.

The prospectus supplement filed for the offering would carry the remaining-ownership figures. Until those are in hand, the confirmed facts are these: 15 million shares at $11.75, an option on 2.25 million more, RBC as sole bookrunner, no proceeds to the company, and settlement on Aug. 24.